13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
38 檔
36.7%
During the Q3 2024 filing period, Nan Fung Group Holdings Ltd (CIK: 0001782539) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $131.5M across 38 reported positions.
During Q3 2024, Nan Fung Group Holdings Ltd's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ILMN | Illumina Inc | Stock-Healthcare | 13.39% | — | — | |
| 2 | HRMY | Harmony Biosciences Holdings | Stock-Other | 12.70% | +0.13% | — | |
| 3 | GERN | Geron CORP | Stock-Other | 5.37% | — | — | |
| 4 | ✓ | Merus N V | Stock-Other | 5.17% | — | — | |
| 5 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 4.89% | — | +327.27% | |
| 6 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 4.61% | — | +11.07% | |
| 7 | OCS | Oculis Holding AG | Stock-Other | 4.61% | -4.52% | — | |
| 8 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.45% | -0.44% | — | |
| 9 | INCY | Incyte CORP | Stock-Healthcare | 4.22% | +0.46% | — | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.62% | — | — | |
| 11 | EXAIEUR | Exscientia PLC | Stock-Other | 3.62% | — | — | |
| 12 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.56% | — | — | |
| 13 | TRML | Tourmaline Bio Inc | Stock-Other | 3.25% | — | — | |
| 14 | LAB | Standard Biotools Inc | Stock-Other | 3.13% | — | — | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.78% | — | — | |
| 16 | REPL | Replimune Group Inc | Stock-Other | 2.72% | — | +40.45% | |
| 17 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.22% | +0.63% | — | |
| 18 | CLYM | Climb Bio Inc | Stock-Other | 2.03% | — | — | |
| 19 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.78% | -0.13% | +71.81% | |
| 20 | ASND | Ascendis Pharma A/S | Stock-Other | 1.75% | -2.57% | EXIT | |
| 21 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.54% | — | -29.53% | |
| 22 | EXEL | Exelixis Inc | Stock-Healthcare | 1.44% | — | — | |
| 23 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.36% | +0.09% | — | |
| 24 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.92% | -0.01% | — | |
| 25 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.68% | -0.24% | — | |
| 26 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.65% | — | — | |
| 27 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.65% | — | — | |
| 28 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.62% | — | +82.57% | |
| 29 | ✓ | Bolt Projs Hldgs Inc | Stock-Other | 0.57% | — | — | |
| 30 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.44% | +0.57% | — | |
| 31 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.29% | +1.20% | — | |
| 32 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 33 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.20% | +0.29% | — | |
| 34 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.18% | — | — | |
| 35 | ✓ | Dbv Technologies S A | Stock-Other | 0.11% | — | — | |
| 36 | ✓ | Affimed N V | Stock-Other | 0.11% | — | — | |
| 37 | ✓ | Stock-Other | 0.09% | — | — | ||
| 38 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 38 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ILMN, HRMY, GERN) accounted for 36.7% of total reported equity market value during Q3 2024.
During Q3 2024, Nan Fung Group Holdings Ltd's top holdings by market value included ILMN (13.4%)、HRMY (12.7%)、GERN (5.4%). The largest single position, ILMN, represented 13.4% of total portfolio value.
In Q3 2024, Nan Fung Group Holdings Ltd made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.